argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 45.13B |
| Revenue (ttm) | 3.14B |
| Net Income (ttm) | 1.31B |
| Shares Out | 61.20M |
| EPS (ttm) | 19.83 |
| PE Ratio | 37.18 |
| Forward PE | 36.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,897 |
| Average Volume | 81,103 |
| Open | 724.00 |
| Previous Close | 723.40 |
| Day's Range | 720.40 - 742.00 |
| 52-Week Range | 456.60 - 754.20 |
| Beta | -0.11 |
| RSI | 66.28 |
| Earnings Date | Oct 30, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
Baron International Growth Fund Q3 2025 Contributors And Detractors
Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geop...
Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP
(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...
Argenx (ARGX) Gains Health Canada Approval for CIDP Treatment
Argenx (ARGX) Gains Health Canada Approval for CIDP Treatment
Biotech is back. Here's why these rallying stocks belong in your portfolio now.
The volatile sector is seeing greater stability, and these four stocks can profit.
ARGX Receives Buy Rating and Raised Price Target by TD Cowen | ARGX Stock News
ARGX Receives Buy Rating and Raised Price Target by TD Cowen | ARGX Stock News
RBC Capital Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
RBC Capital Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
Evercore ISI Group Raises Price Target for argenx (ARGX) to $910 | ARGX Stock News
Evercore ISI Group Raises Price Target for argenx (ARGX) to $910 | ARGX Stock News
argenx SE (ARGX) Q3 2025 Earnings Call Transcript
argenx SE ( ARGX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - C...
argenx SE (ARGNF) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Pipeline Advancements
argenx SE (ARGNF) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Pipeline Advancements
Q3 2025 argenx SE Earnings Call Transcript
Q3 2025 argenx SE Earnings Call Transcript
argenx SE 2025 Q3 - Results - Earnings Call Presentation
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.
Argenx (ARGX) Reports Strong Q3 Earnings and Revenue Growth
Argenx (ARGX) Reports Strong Q3 Earnings and Revenue Growth
argenx SE beats top-line and bottom-line estimates; reaffirms FY25 outlook
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any b...
Argenx (ARGX) Reports Positive Results for Vyvgart in Myasthenia Gravis Study
Argenx (ARGX) Reports Positive Results for Vyvgart in Myasthenia Gravis Study
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results sho...
argenx SE Q3 2025 Earnings Preview
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 11.18% on an annualized basis producing an average annual return of 25.76%. Currently, argenx has a market capitalization of...
argenx Reaches Analyst Target Price
In recent trading, shares of argenx SE (Symbol: ARGX) have crossed above the average analyst 12-month target price of $826.86, changing hands for $837.28/share. When a stock reaches the target an anal...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained...
How Do Investors Really Feel About argenx SE?
argenx SE's (NYSE: ARGX) short interest as a percent of float has fallen 4.76% since its last report. According to exchange reported data, there are now 1.67 million shares sold short , which is 3.0%...
Wedbush Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
Wedbush Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...